Is sofosbuvir and velpatasvir (Epclusa) on the market?

In June 2016, the U.S. Food and Drug Administration (FDA) approved sofosbuvir and velpatasvir (Epclusa) as a fixed-dose combination, the first to treat all genotypes. The combination HCV product for hepatitis C (with or without cirrhosis) is also the most effective antiviral drug for HCV currently on the market, with sustained virological response (SVR) of 93-99% after 12 weeks of treatment, depending on genotype and cirrhosis level. Sofosbuvir and velpatasvirare listed as first-line recommended drugs for all HCV genotypes.

This combination of sofosbuvir and velpatasvir is approved in the United States to treat hepatitis C virus (HCV) in children 6 years and older or weighing at least 37 pounds (17 kilograms) who have any of six HCV genotypes or strains and do not have cirrhosis (liver disease) or have mild cirrhosis. The combination of sofosbuvir and velpatasvir in combination with ribavirin is indicated for the treatment of children with severe cirrhosis who are 6 years of age and older or who weigh at least 37 pounds.

The original drug of sofosbuvir and velpatasvir has been launched in China and has entered the scope of Class B medical insurance. The domestic trade name is protonsa, and the specification is (400mg+100mg) * 28 tablets. The price per box is about RMB 4,000. The original drug of sofosbuvir and velpatasvir has also been launched overseas. There are also generic drugs of sofosbuvir and velpatasvir produced in other countries. The specifications of the Bangladesh Everest Pharmaceutical Factory are (400mg + 100mg) * 28 tablets per box, and the price is around RMB 850 (the price may fluctuate due to the exchange rate). The generic drugs produced abroad are basically the same as the original drugs at home and abroad.